See the DrugPatentWatch profile for Golodirsen
What are practical alternatives to golodirsen (Vyondys 53) for Duchenne muscular dystrophy?
Golodirsen (Vyondys 53) is an antisense oligonucleotide designed to induce skipping of specific dystrophin exons in Duchenne muscular dystrophy (DMD). Alternatives generally fall into two buckets: other exon-skipping drugs for different target exons, or non–exon-skipping therapies.
Which option fits depends on the patient’s dystrophin gene mutation and the specific exon(s) that must be skipped to restore the reading frame.
Which exon-skipping drugs are used instead of golodirsen?
If a patient’s mutation supports it (based on which exon skipping is needed), clinicians can use other antisense therapies that target different exons rather than exon 53—the key target for golodirsen. The “alternative” is determined by the exon that matches the patient’s genotype.
What non–exon-skipping treatments are alternatives?
When exon-skipping is not appropriate, or in addition to exon-skipping, clinicians may consider other DMD treatments that work through different mechanisms (for example, therapies aimed at muscle function, inflammation/modifying disease course, or protein stabilization). The right choice depends on eligibility, age, disease stage, and mutation details.
How do you choose the right alternative for a specific patient?
The usual decision pathway is:
1) Confirm the patient’s dystrophin mutation and identify which exon(s) can be skipped.
2) Match that exon target to the corresponding antisense therapy (if available and appropriate).
3) If exon-skipping does not fit, consider other approved DMD options based on mechanism and eligibility.
Can someone switch from golodirsen to another therapy?
Switching may be considered if:
- The patient’s genotype suggests a different exon-skipping target.
- Treatment goals change (tolerability, response, logistics).
- A different therapy is clinically more suitable for the patient’s stage of DMD.
The switch decision is individualized and typically coordinated by a neuromuscular specialist.
What side effects and monitoring are typically considered when switching?
Exon-skipping antisense therapies can require ongoing monitoring (commonly including kidney-related checks and planned dosing schedules). If switching, clinicians usually review:
- Prior safety and tolerability
- Ongoing labs/monitoring requirements
- The expected mechanism for the patient’s specific exon target
If you share the patient’s exon target (or mutation, if you have it) and age/stage, I can narrow down which categories of alternatives best match that situation.